Cancer Vaccines Market Size, Demand, Growth, Challenges and Future Competition 2022-2032

Cancer Vaccines Market Size– By Technology, By Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Cancer Vaccines Market Size– By Technology, By Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Published: Dec 2022 Report ID: HLCA2233 Pages: 1 - 242 Formats*:     
Category : Healthcare
Global Cancer Vaccines Market Overview:

According to SPER Market Research, the Global Cancer Vaccines Market is estimated to reach USD 20.09 billion by 2032 with a CAGR of 12.82%. 

Vaccines are medications that boost the body's immune system to defend it from foreign substances. Cancer vaccines are medicines that act as biological response modifiers. Foreign bodies are destroyed by an activated immune system. Vaccines function on the theory of memorizing foreign particles and preventing illness caused by these foreign particles when they invade again. Cancer vaccines are classified as biological response modifiers. These modifiers function by activating the immune system to combat illness. Broadly, cancer vaccines are of two types: prevention vaccines and treatment vaccines. In order to prevent cancer, healthy people are given preventive cancer vaccinations. Patients with cancer are given therapeutic cancer vaccines to boost their immune system's ability to combat the disease. Cancer vaccinations can be given intravenously (IV) to both adults and children.

Impact of COVID-19 on the Global Cancer Vaccines Market
The market for Global Cancer Vaccines Market production and distribution firms have been impacted to a limited amount by COVID-19, owing to shutdowns in various COVID-19 afflicted nations and an increase in the number of healthcare professionals becoming ill in the of the pandemic, resulting in low supply. The pandemic has hampered cancer vaccine manufacturing as well as the import and export of raw materials and completed goods owing to shutdowns in various COVID-19-affected nations. Due to rising product approvals in emerging nations and major industry players' increased focus on clinical research for the development of innovative vaccines, the pandemic also drove the market. The pandemic reduced the population's rate of cancer vaccination, but growing consumer awareness and a high demand for cancer vaccines are two instances of the market's slow growth.




Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Technology, By Type, By Indication, By End User
 Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.
Global Cancer Vaccines Market Segmentation:

By Technology:  Based on the Technology, Global Cancer Vaccines Market is segmented as; Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines.

By Type: Based on the Type, Global Cancer Vaccines Market is segmented as; Preventive Cancer Vaccines, Therapeutic Cancer Vaccines.

By Indication: Based on the Indication, Global Cancer Vaccines Market is segmented as; Cervical Cancer, Prostate Cancer Others.

By End User: 
Based on the End User, Global Cancer Vaccines Market is segmented as; Pediatrics, Adults.

By Region: Due to rising cancer fatalities, North America is expected to account for the highest proportion of the global cancer vaccines market. Due to growing government initiatives, businesses focusing more on the India vaccine technology market, and growing immunisation programmes by the World Health Organization and GAVI, Asia Pacific is anticipated to have the most growth. 
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
 
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
 
3. Executive Summary
 
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Cancer Vaccines Market 
 
5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4.Heat map analysis
 
6. Global Cancer Vaccines Market, By Technology, 2019-2032 (USD Million)
6.1. Antigen/Adjuvant Cancer Vaccines
6.2. Dendritic Cells (DC) Cancer Vaccines
6.3. Recombinant Cancer Vaccines
6.4. Viral Vector & DNA Cancer Vaccines

7. Global Cancer Vaccines Market, By Type, 2019-2032 (USD Million)
7.1. Preventive Cancer Vaccines
7.2. Therapeutic Cancer Vaccines 

8. Global Cancer Vaccines Market, By Indication, 2019-2032 (USD Million)
8.1. Cervical Cancer 
8.2. Prostate Cancer 
8.3. Others.

9. Global Cancer Vaccines Market, By End User, 2019-2032 (USD Million)
9.1. Pediatrics 
9.2. Adults 

10. Global Cancer Vaccines Market, By Region, 2019-2032 (USD Million)
10.1. North America
10.1.1. Canada
10.1.2. Mexico
10.1.3. United States
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Rest of Europe
10.2.5. Spain
10.2.6. United Kingdom
10.3. Asia-Pacific
10.3.1. Australia
10.3.2. China
10.3.3. India
10.3.4. Japan
10.3.5. Rest of Asia-Pacific
10.3.6. South Korea
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia 
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa

11. Company Profiles
11.1. Aduro Biotech
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments

11.2. Advantagene
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments

11.3. Advaxis 
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments

11.4. Agenus
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments

11.5. Altor BioScience
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments

11.6. Argos Therapeutics
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments

11.7. Dendreon
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments

11.8. GlaxoSmithKline
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments

11.9. OncoThyreon
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments

11.10. Oncovir 
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments

11.11. Oxford BioMedical
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments

11.12. Prsima BioMed
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments

11.13. Sotio
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments

11.14. Transgene
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments

11.15. Ubivac
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments

11.16. Vaccinogen
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments

11.17. Vaxon Biotech
11.17.1. Company details
11.17.2. Financial outlook
11.17.3. Product summary
11.17.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The Cancer Vaccines Market is projected to reach USD 20.09 billion by 2032, growing at a CAGR of 12.82% during the forecast period.
The Cancer Vaccines Market grew in market size from 2021. The Market is expected to reach USD 20.09 billion by 2032, at a CAGR of 12.82% during the forecast period.
The Cancer Vaccines Market CAGR of 12.82% during the forecast period.
You can get the sample pages by clicking the link -Click Here
The Cancer Vaccines Market size is USD 20.09 billion from 2022 to 2032.
The Cancer Vaccines Market segment is Covered By Technology, By Type, By Indication, By End User.
The North America and Europe region is anticipated to have the highest market share in the Cancer Vaccines Market.
The key players in the market include Companies Covered Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.
Cancer vaccines are classified as biological response modifiers. These modifiers function by activating the immune system to combat illness. Broadly, cancer vaccines are of two types: prevention vaccines and treatment vaccines. In order to prevent cancer, healthy people are given preventive cancer vaccinations.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us